Inhaled Phage Therapy in Critically Ill Patients: New Clinical Evidence from a 96-Patient Study

A new investigation into inhaled bacteriophage therapy

The clinical development of bacteriophage therapy is increasingly exploring administration routes beyond conventional intravenous and topical applications. Among these approaches, inhalation offers an interesting possibility for treating respiratory infections by delivering bacteriophages directly to the respiratory tract.

A new study published on November 12, 2026, in Frontiers in Medicine provides additional clinical data on this strategy. Entitled Hospital-adapted inhaled phage cocktail as a component of antimicrobial therapy in chronically critically ill patients with lower respiratory tract infections, the research examines whether inhaled bacteriophages can be safely incorporated into antibiotic treatment and potentially contribute to antimicrobial stewardship.

Inhaled bacteriophage therapy: phages are delivered directly to the respiratory tract using a nebulizer. Illustrative photograph; the patient is not part of the 2026 Frontiers in Medicine study.

The investigators analysed 96 chronically critically ill patients with lower respiratory tract infections. Fifty-six received systemic antibiotics combined with inhaled bacteriophages, while 40 received antibiotics alone. The phage preparation was administered three times daily over a 21-day period.

The findings provide further information on the feasibility and short-term tolerability of inhaled phage therapy. However, the study did not demonstrate statistically significant improvements in the main clinical, inflammatory or microbiological outcomes compared with antibiotics alone. One particularly interesting observation concerned the escalation of antibiotic treatment, suggesting a possible role for phages in reducing reliance on more restricted antimicrobial agents.

A vulnerable population with difficult-to-treat respiratory infections

The study was conducted at the Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology in Moscow, Russia. It focused on adults experiencing chronic critical illness following severe brain injuries, including stroke, traumatic brain injury and anoxic brain injury.

These patients had previously spent at least 21 days in intensive care and required ongoing medical support, including tracheostomy and management of impaired consciousness. Their prolonged hospitalization and respiratory complications expose them to an increased risk of infections involving multidrug-resistant hospital pathogens.

All patients included in the analysis had confirmed lower respiratory tract infections requiring systemic antimicrobial treatment. This provided an opportunity to investigate the potential contribution of phages as an adjunct to conventional antibiotics rather than as a replacement for standard antimicrobial therapy.

Importantly, the 2026 publication is a post hoc secondary analysis of prospectively collected data from a randomized controlled study. The investigators specifically selected patients who were receiving systemic antibiotics at baseline, allowing them to examine the addition of inhaled phages within this treatment context.

Bronchophage: a hospital-adapted cocktail targeting nosocomial pathogens

One of the most interesting aspects of the study is the use of Bronchophage, a hospital-adapted bacteriophage preparation developed by Research and Production Center MicroMir.

Unlike a preparation individually formulated for every patient, this cocktail was periodically updated according to the bacterial pathogens circulating within the hospital. At least once every three months, bacterial isolates collected through local microbiological surveillance were sent to the manufacturer's laboratory, where suitable lytic bacteriophages were selected using spot testing.

The resulting preparation contained up to 50 bacteriophages targeting important respiratory pathogens, including Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Enterobacter cloacae and Staphylococcus species.

This approach is particularly relevant in intensive care units, where the bacterial populations responsible for hospital-acquired infections can change over time. Periodically adapting the cocktail to local microbiological epidemiology may help maintain activity against prevalent hospital strains.

Patients in the intervention group received 5 mL of Bronchophage by inhalation three times daily for 21 days, in addition to their systemic antibiotics. The control group received antibiotics alone.

The distinction between hospital-adapted and fully personalized phage therapy remains important. In this study, the cocktail was adjusted according to the hospital's circulating pathogens rather than being individually formulated for each patient's bacterial isolate.

Short-term safety and tolerability

One of the principal objectives was to evaluate whether inhaled bacteriophages could be administered safely to patients with complex medical conditions.

During the 21-day observation period, the investigators reported no clinically apparent treatment-limiting adverse events attributable to phage administration. No allergic reactions were recorded.

The researchers also monitored biochemical markers associated with hepatic and renal function, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin and creatinine. No statistically significant differences between the intervention and control groups were identified for these parameters at day 21.

These observations provide encouraging information about the short-term tolerability of inhaled phage preparations in this particular population. Nevertheless, the relatively small sample and limited follow-up prevent definitive conclusions about long-term safety or the generalizability of these findings to other patient groups.

Clinical and microbiological outcomes: encouraging trends without significant differences

The researchers also investigated changes in inflammatory markers, chest computed tomography findings and microbiological results obtained from bronchoalveolar lavage samples.

At day 21, the main between-group comparisons did not demonstrate statistically significant differences in C-reactive protein (CRP), chest CT scores or bronchoalveolar lavage culture scores.

Some numerical differences nevertheless deserve attention. A reduction in microbial burden was observed in 32.1% of patients receiving antibiotics and phages, compared with 15.4% of patients receiving antibiotics alone. However, this difference did not reach conventional statistical significance (p = 0.064).

Within the phage-treated group, CRP levels and chest CT scores decreased significantly between baseline and day 21. These changes were statistically significant in the intervention group, with p-values of 0.043 and 0.046, respectively.

However, improvements observed within one treatment group cannot independently establish a treatment effect. The relevant question is whether the improvement was significantly greater than that observed in the control group. In this study, the corresponding between-group differences were not statistically significant.

The findings therefore suggest possible favourable trends, but they do not establish that adding inhaled phages improved respiratory infection outcomes compared with antibiotics alone.

Could inhaled phages reduce the need for Reserve antibiotics?

Perhaps the most interesting finding concerns antimicrobial stewardship.

The investigators examined whether the addition of phages was associated with a reduced need to escalate antibiotic treatment from the Watch category to the Reserve category under the World Health Organization's AWaRe classification.

This analysis was restricted to patients receiving Watch-group antibiotics at baseline, comprising 41 patients in the intervention group and 31 in the control group.

The cumulative proportion of patients requiring escalation to Reserve antibiotics was lower in the phage-treated group at all three assessment points. At day 7, the proportions were 9.8% in the intervention group and 16.1% in controls. At day 14, they were 12.2% and 32.3%, respectively. At day 21, the corresponding figures were 14.6% and 32.3%.

The difference reached nominal statistical significance only at day 14 (p = 0.038). The comparisons at day 7 and day 21 were not statistically significant.

This observation raises an interesting possibility: inhaled phage therapy could potentially contribute to antimicrobial stewardship by helping reduce the need for escalation towards antibiotics reserved for infections with limited treatment options.

Preserving the effectiveness of these antibiotics is a major challenge in intensive care, particularly in patients repeatedly exposed to antimicrobial treatments.

However, this result must be interpreted cautiously. The analysis was exploratory, several outcomes and time points were investigated, and no correction for multiple statistical comparisons was applied. The day-14 finding therefore requires confirmation in larger, independently conducted studies.

An important limitation: overlap with a previous publication

An important methodological detail concerns the relationship between this study and an earlier publication from the same research group.

Although the 2026 analysis includes 96 patients, 29 of these patients had already been included in a previous publication, all belonging to the phage intervention group. The remaining 67 patients had not previously been reported.

The earlier study, published in 2021 in General Reanimatology, investigated adaptive inhaled phage therapy in 83 chronically critically ill patients. It included patients receiving phages alongside antibiotics as well as patients receiving phages without concomitant antibiotics.

The new analysis addresses a more specific research question by focusing on patients receiving systemic antibiotics at baseline. It also introduces an assessment of antibiotic escalation according to the WHO AWaRe classification, an outcome not examined in the same way in the previous publication.

The reuse of previously collected data is not inherently problematic when the overlap is transparently disclosed and the new analysis addresses a distinct research question. Nevertheless, the 96 patients should not be interpreted as 96 entirely new and independent clinical observations.

This distinction matters when assessing the cumulative clinical evidence for phage therapy. Counting overlapping patients across publications as independent cases could overestimate the amount of clinical experience available in the literature.

What comes next for inhaled phage therapy?

This study contributes additional information to the development of inhaled bacteriophage therapy, particularly in a population for whom respiratory infections and multidrug-resistant pathogens represent substantial clinical challenges.

Its results support the feasibility of incorporating a hospital-adapted phage cocktail into existing antibiotic treatment protocols. They also suggest that the potential contribution of phages should be investigated beyond direct bacterial eradication, including their possible role in antimicrobial stewardship.

However, several questions remain unanswered. The single-centre design, relatively limited sample size and 21-day follow-up restrict the conclusions that can be drawn. Moreover, the absence of statistically significant differences in the main clinical and microbiological comparisons means that improved treatment efficacy has not been demonstrated.

Future multicentre trials should investigate whether these observations can be reproduced in larger populations. They should also examine longer-term microbiological outcomes, recurrence rates, antibiotic consumption and the potential differences between hospital-adapted cocktails and phage preparations selected for individual patients.

Conclusion

The November 2026 Frontiers in Medicine study provides further clinical information on inhaled bacteriophage therapy as an adjunct to antibiotics in chronically critically ill patients with lower respiratory tract infections.

Among 96 patients, the addition of inhaled phages was feasible and was not associated with reported treatment-limiting adverse events during the 21-day observation period. Although some favourable numerical trends were observed, the principal between-group clinical and microbiological comparisons did not reach statistical significance.

The lower frequency of escalation to Reserve antibiotics at day 14 represents an interesting finding that deserves further investigation, but it remains exploratory. The overlap with 29 patients from a previous publication must also be considered when interpreting the overall clinical evidence.

The main contribution of this research is therefore additional evidence on the feasibility and short-term tolerability of inhaled phage therapy, rather than proof of improved clinical efficacy.

Larger, independent and multicentre studies will be essential to determine whether this approach can become a reliable component of antimicrobial treatment for difficult-to-treat respiratory infections.



References :

Chernevskaya E, Grechko A, Gurkova M, et al. (2026). Hospital-adapted inhaled phage cocktail as a component of antimicrobial therapy in chronically critically ill patients with lower respiratory tract infections. Frontiers in Medicine, 13:1974589. Published November 12, 2026. https://doi.org/10.3389/fmed.2026.1974589

Beloborodova NV, Grechko AV, Gurkova MM, et al. (2021). Adaptive Phage Therapy in the Treatment of Patients with Recurrent Pneumonia (Pilot Study). General Reanimatology, 17(6):4–14. https://doi.org/10.15360/1813-9779-2021-6-4-14

Comments

Most Consulted Articles

Bacteriophages Disarm Inflammation-Associated E. coli Without Erasing the Gut Microbiome in IBD

🌐 PhageAtLabs® — a global interactive mapping of academic laboratories in phage research.

History Part 12 : Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s)

The Phage Therapy in the spotlight !

Phagos Launches CAPHARD, a 900-Million-Parameter AI Model to Predict Phage–Bacteria Interactions